- Home
- DRUG vs ACV Comparison
DRUG vs ACV Comparison
Compare DRUG & ACV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- ACV
- Stock Information
- Founded
- DRUG 2019
- ACV 2015
- Country
- DRUG United States
- ACV United States
- Employees
- DRUG N/A
- ACV N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- ACV Finance/Investors Services
- Sector
- DRUG Health Care
- ACV Finance
- Exchange
- DRUG Nasdaq
- ACV Nasdaq
- Market Cap
- DRUG 210.7M
- ACV 222.0M
- IPO Year
- DRUG N/A
- ACV N/A
- Fundamental
- Price
- DRUG $32.38
- ACV $22.10
- Analyst Decision
- DRUG
- ACV
- Analyst Count
- DRUG 0
- ACV 0
- Target Price
- DRUG N/A
- ACV N/A
- AVG Volume (30 Days)
- DRUG 382.4K
- ACV 38.8K
- Earning Date
- DRUG 11-26-2024
- ACV 01-01-0001
- Dividend Yield
- DRUG N/A
- ACV 9.20%
- EPS Growth
- DRUG N/A
- ACV N/A
- EPS
- DRUG N/A
- ACV N/A
- Revenue
- DRUG N/A
- ACV N/A
- Revenue This Year
- DRUG N/A
- ACV N/A
- Revenue Next Year
- DRUG N/A
- ACV N/A
- P/E Ratio
- DRUG N/A
- ACV N/A
- Revenue Growth
- DRUG N/A
- ACV N/A
- 52 Week Low
- DRUG $0.93
- ACV $16.82
- 52 Week High
- DRUG $79.02
- ACV $23.74
- Technical
- Relative Strength Index (RSI)
- DRUG 43.69
- ACV 60.88
- Support Level
- DRUG $36.02
- ACV $21.28
- Resistance Level
- DRUG $44.70
- ACV $22.34
- Average True Range (ATR)
- DRUG 5.79
- ACV 0.29
- MACD
- DRUG -3.22
- ACV 0.05
- Stochastic Oscillator
- DRUG 6.26
- ACV 80.75
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About ACV Virtus Diversified Income & Convertible Fund of Beneficial Interest
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation while seeking to provide downside protection against capital loss. It seeks to achieve its investment objective by investing in a combination of convertible securities, debt and other income-producing instruments and common stocks and other equity securities.